<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04626128</url>
  </required_header>
  <id_info>
    <org_study_id>CLS1002-101</org_study_id>
    <nct_id>NCT04626128</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD</brief_title>
  <acronym>OASIS</acronym>
  <official_title>OASIS: Open-label, Dose-escalation, Phase 1/2a Study of the Safety and Tolerability of Suprachoroidally Administered CLS-AX Following Intravitreal Anti-VEGF Therapy in Subjects With Neovascular Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clearside Biomedical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clearside Biomedical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of suprachoroidally administered CLS-AX following&#xD;
      intravitreal anti-VEGF therapy in subjects with neovascular age-related macular degeneration&#xD;
      (AMD)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center, open-label, dose-escalation, phase 1/2a, safety and tolerability study to&#xD;
      evaluate three dose groups of suprachoroidally administered CLS-AX following intravitreal&#xD;
      anti-VEGF therapy in subjects with neovascular age-related macular degeneration&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Three groups of approximately 5 participants are assigned to receive interventions in sequential dose escalation fashion based on prior milestones being reached.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>The summary of adverse events and serious adverse events will be based on the Safety Population and will be limited to TEAEs. A TEAE is any adverse event occurring on or after the date and time of the SC injection of CLS-AX administration at Baseline (Visit 2) or worsening relative to the pre CLS-AX state.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pre injection Intraocular Pressure (IOP)</measure>
    <time_frame>Day 1 to Week 12</time_frame>
    <description>Changes from Baseline (Visit 2) pre injection IOP values in the study eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of subjects receiving additional intravitreal (IVT) aflibercept injections</measure>
    <time_frame>Day 1 to Week 12</time_frame>
    <description>Number of subjects receiving additional intravitreal injections during the course of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of subjects qualifying to receive additional intravitreal (IVT) aflibercept injections</measure>
    <time_frame>Day 1 to Week 12</time_frame>
    <description>Number of subjects qualifying to receive additional intravitreal injections during the course of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline (Visit 2) in central subfield retinal thickness (CST) in the study eye</measure>
    <time_frame>Day 1 to Week 12</time_frame>
    <description>Mean change from Baseline (Visit 2) values in CST during the course of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline (Visit 2) in best corrected visual acuity (BCVA) letter score in the study eye</measure>
    <time_frame>Day 1 to Week 12</time_frame>
    <description>Mean change from Baseline (Visit 2) values in BCVA during the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration [Cmax] of axitinib</measure>
    <time_frame>Day 1 to Week 12</time_frame>
    <description>Maximum (or peak) plasma concentration of axitinib during the course of the study</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (Low Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a low dose of 0.03 mg CLS-AX</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (Middle Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a middle dose of 0.10 mg CLS-AX</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (High Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a high dose of 0.30 mg CLS-AX</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CLS-AX</intervention_name>
    <description>injectable suspension of small molecule tyrosine kinase inhibitor (TKI)</description>
    <arm_group_label>Cohort 1 (Low Dose)</arm_group_label>
    <arm_group_label>Cohort 2 (Middle Dose)</arm_group_label>
    <arm_group_label>Cohort 3 (High Dose)</arm_group_label>
    <other_name>axitinib injectable suspension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-VEGF</intervention_name>
    <description>Standard of care therapy used to block vascular endothelial growth factor</description>
    <arm_group_label>Cohort 1 (Low Dose)</arm_group_label>
    <arm_group_label>Cohort 2 (Middle Dose)</arm_group_label>
    <arm_group_label>Cohort 3 (High Dose)</arm_group_label>
    <other_name>aflibercept (2mg)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of neovascular age-related macular degeneration in the study eye.&#xD;
&#xD;
          -  Active subfoveal choroidal neovascularization (CNV) secondary to AMD&#xD;
&#xD;
          -  Two or more prior anti-VEGF intravitreal injections&#xD;
&#xD;
          -  EDTRS BCVA score ≤ 75 and ≥ 20 letters&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any active ocular disease, ocular disorders or conditions, prior ocular surgery or&#xD;
             infection in the study eye other than nAMD&#xD;
&#xD;
          -  Other than IVT anti-VEGF treatments, no topical ocular or intraocular or periocular&#xD;
             corticosteroid, or other treatments for CNV&#xD;
&#xD;
          -  IOP ≥ 25mmHg or cup-to-disc ratio &gt;0.8&#xD;
&#xD;
          -  Uncontrolled systemic disease (high risk or evidence of arterial and venous&#xD;
             thromboembolism, CVA or stroke, unstable cardiovascular disease, uncontrolled&#xD;
             hyperthyroidism, poor glycemic control, gastrointestinal bleed and/or high risk of GI&#xD;
             perforation or fistula formation) or any other condition or therapy that would make&#xD;
             the participant unsuitable for the study&#xD;
&#xD;
          -  Currently enrolled in an investigational drug or device study or has used an&#xD;
             investigational drug or device within 30 days or the Screening visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Ciulla, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Clearside Biomedical, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retinal Consultants of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern California Retina Vitreous Associates Medical Group, LLC</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cumberland Valley Retina Consultants</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Texas</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Texas</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMD</keyword>
  <keyword>Wet-AMD</keyword>
  <keyword>suprachoroidal</keyword>
  <keyword>tyrosine kinase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
    <mesh_term>Axitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

